Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 5/20 | 0.40 |
| ▸ | THRB | P10828 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5587174 | 0.88 | THRA (0.37) | GABRA1GABRB1THRATHRBLMNA | |
| SCHEMBL5588330 | 0.84 | THRA (0.35) | GABRA1GABRB1THRATHRBEIF4A3 | |
| SCHEMBL5586591 | 0.84 | THRA (0.43) | GABRA1GABRB1THRATHRBLDHA | |
| SCHEMBL5588667 | 0.83 | PKM (0.38) | GABRA1GABRB1THRATHRBLMNA | |
| SCHEMBL5588814 | 0.80 | TSHR (0.36) | THRATHRBGLRA1 | |
| SCHEMBL5588051 | 0.77 | LDHA (0.31) | LDHALDHB | |
| SCHEMBL5586857 | 0.77 | RXRA (0.39) | THRATHRBGLRA1 | |
| SCHEMBL5588527 | 0.76 | PTGDR2 (0.38) | THRATHRB | |
| SCHEMBL5587405 | 0.76 | RXRA (0.40) | THRATHRB | |
| SCHEMBL5586987 | 0.75 | GABRA1 (0.43) | GABRA1GABRB1THRATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | GABRA1 3688/4885GABRB1 3446/4885THRA 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.